Wellstar International, Inc. Announces Success in Beta Test

Wellstar International, Inc. (OTCBB:WLSI) (“Wellstar”) has announced that it is achieving success in their Beta Test in a long term acute care facility (LTAC).

Wellstar has been imaging existing patients and newly admitted patients twice a week in one of its Beta Test Long Term Care Facilities. The system is successfully tracking existing wounds as well as deep tissue injury that ultimately leads to a pressure ulcer. This allows the facility to give their patients additional preventative and ongoing care.

Wellstar’s goal is to be able to detect a deep tissue injury and have the facility treat the injury so that it possibly never becomes a pressure ulcer. To date Wellstar TMI Imaging System has been able to detect deep tissue injuries as well as other ulcers that would have gone otherwise unnoticed by the care givers until the ulcer broke the skin, as the System can detect what the nurse or doctor cannot see with the naked eye.

The TMI System becomes a very cost effective tool because if an ulcer breaks the skin, the cost could average almost 40,000 dollars to treat and close the sore. As Wellstar continues to see growing successes in their Beta Trials, they should be in a position to go to market within the next 6-7 months.

Wellstar International, Inc. seeks to be the first-to-market in deep tissue injury and pressure ulcer detection using its proprietary infrared imaging system. Thermal Imaging is a low cost, noncontact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition, thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner. Thermal Imaging can detect signs of pressure ulcers before they are visible with the naked eye through detection of temperature changes at the site which allows for treatment of the pressure ulcer before it erupts. The TMI system can be used to scan all new patients into hospitals and long-term care facilities prior admittance and begin treating existing wounds before they are visible.

Wellstar’s believes that the first emphasis on marketing their systems will be to the LTAC Industry. There are over 700 of these facilities in the US and their uses will correlate with the facilities that are involved or will be involved with the Beta Test. This should lead to over 1 million dollars per month in revenue for Wellstar.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.

Wellstar (CE) (USOTC:WLSI)
Historical Stock Chart
From Nov 2024 to Dec 2024